科莫非对维持性血液透析患者肾性贫血的疗效观察  

Clinical observation of Cosmofer in treatment of renal anemia in mainteance hemodialysis patients

作　　者：陈侣林[1] 饶进[1] 徐秀蓉[1] 谷粒[1] 刘俊[1] 贾丽娟[1] 

机构地区：[1]成都铁路中心医院内科,四川成都610081

出　　处：《四川医学》2008年第9期1149-1150,共2页Sichuan Medical Journal

摘　　要：目的探讨科莫非治疗维持性血液透析患者肾性贫血的疗效。方法治疗组30例采用科莫非100mg加生理盐水100ml于血液透析结束后静脉滴注,每周2次,共6周。对照组30例,口服力蜚能150mg,1次/d,疗效观察6周。所有患者均给予适量促红细胞生成素(EPO)等常规治疗。记录两组每位患者治疗前后的血红蛋白(Hb)、红细胞数(RBC)、血细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)。结果口服力蜚能组患者SF、TSAT治疗前后有统计学意义(P<0.05),但不如治疗组显著,血红蛋白的增长也不理想。而科莫非组SF、TSAT均显著提高(P<0.01),明显优于口服力蜚能组。结论科莫非能迅速有效地纠正接受EPO治疗的维持性血液透析患者的肾性贫血。Objective To observe the effects of cosmofer in treatment of renal anemia in maintaining hemodialysis patients. Methods 60 patients were divided into intravenous iron group （ n = 30 ） and oral iron group （ n = 30） . 100mg cosmofer that was dissolved in 100ml of 0.9% Nacl solution was used twice a week and 6 weeks in eosmofer group. Patiens in oral iron group took 150mg Niferex daily for 6 weeks. All patients in the two groups were assigned recombinant human erythropoietin （EPO ）. There hemoglobin （Hb）, Red blood cell count （ RbC ）, Hematocrit （ HCT ） , Serum ferrin （ SF ） , Serum transferring receptor （ TSAT ） were measured at the beganing and the end of the study. Results All of the variables were significandy increases in cosmofer group than in Niferex group. Conclusion cosmofer is quick and effective on improvement of renal anemia in maintenance hemodialysis patients.

关 键 词：肾性贫血 科莫非 血液透析 

分 类 号：R692.5[医药卫生—泌尿科学]